Valneva SE Sponsored ADR (NASDAQ:VALN) Short Interest Update

Key Points

• Valneva SE experienced a significant decrease in short interest, dropping by 33.7% to 12,400 shares as of September 30th, marking an overall short-interest ratio of 0.1 days.
• Equities research analysts have differing views on Valneva, with Weiss Ratings maintaining a sell rating, while three analysts recommend a buy and one a hold, leading to an overall consensus rating of Moderate Buy.
• Valneva's market capitalization stands at $848.13 million, with its stock trading at $9.87, and analysts expecting an EPS of $0.13 for the current year.

Valneva SE Sponsored ADR (NASDAQ:VALN - Get Free Report) saw a large drop in short interest in September. As of September 30th, there was short interest totaling 12,400 shares, a drop of 33.7% from the September 15th total of 18,700 shares. Currently, 0.0% of the company's stock are short sold. Based on an average daily volume of 92,500 shares, the short-interest ratio is presently 0.1 days. Based on an average daily volume of 92,500 shares, the short-interest ratio is presently 0.1 days. Currently, 0.0% of the company's stock are short sold.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on VALN shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Valneva in a research report on Wednesday, October 8th. Wall Street Zen raised Valneva to a "hold" rating in a research report on Saturday, September 6th. Jefferies Financial Group set a $14.00 price objective on Valneva and gave the company a "buy" rating in a report on Monday, August 25th. Guggenheim dropped their price objective on Valneva from $14.00 to $13.00 and set a "buy" rating on the stock in a report on Monday, September 8th. Finally, HC Wainwright reiterated a "buy" rating and issued a $18.00 price objective on shares of Valneva in a report on Monday, August 25th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $15.00.

Hedge Funds Weigh In On Valneva

Hedge funds and other institutional investors have recently bought and sold shares of the company. Frazier Life Sciences Management L.P. acquired a new position in shares of Valneva in the second quarter worth $8,240,000. GAMMA Investing LLC acquired a new position in shares of Valneva in the first quarter worth $94,000. Finally, Marex Group plc acquired a new position in shares of Valneva in the second quarter worth $64,000. 11.39% of the stock is owned by institutional investors and hedge funds.

Valneva Trading Down 0.9%

NASDAQ:VALN opened at $9.87 on Wednesday. The stock's 50 day moving average price is $10.11 and its 200 day moving average price is $7.78. The company has a market capitalization of $848.13 million, a PE ratio of -10.07 and a beta of 1.86. The company has a quick ratio of 1.77, a current ratio of 2.27 and a debt-to-equity ratio of 0.66. Valneva has a 52-week low of $3.62 and a 52-week high of $12.25.

Valneva (NASDAQ:VALN - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.11. The company had revenue of $54.84 million for the quarter, compared to the consensus estimate of $46.28 million. Valneva had a negative return on equity of 34.78% and a negative net margin of 33.87%. On average, research analysts anticipate that Valneva will post 0.13 EPS for the current year.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.